1.70Open1.55Pre Close24 Volume18 Open Interest32.50Strike Price3.90KTurnover166.11%IV1.30%PremiumMay 9, 2025Expiry Date1.36Intrinsic Value100Multiplier1DDays to Expiry0.44Extrinsic Value100Contract SizeAmericanOptions Type0.7196Delta0.1317Gamma18.55Leverage Ratio-0.5838Theta0.0005Rho13.35Eff Leverage0.0052Vega
TG Therapeutics Stock Discussion
TG Therapeutics Crushes Earnings: MS Drug BRIUMVI Drives 137% Growth, Company Turns Profitable
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short
How TG Therapeutics Transformed from Clinical-Stage to Profitable Biotech with 250% Revenue Growth
Can BRIUMVI Succeed Where Other MS Treatments Failed? New Clinical Data Reveals Promising Results
Larger Image: tradingview.com...
$TG Therapeutics (TGTX.US)$
No comment yet